Akorn (NASDAQ:AKRX) has received a new Abbreviated New Drug Application (ANDA) approval from the FDA for Bimatoprost Ophthalmic Solution, 0.03%.
According to IQVIA, sales of bimatoprost ophthalmic solution, 0.03% were ~$63.5M for the year ended August 2018.
Bimatoprost ophthalmic solution, 0.03% is indicated to treat hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness.
Shares are up 8% premarket.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.